2. Academic Validation
  3. Antimycobacterial activity of new N(1)-[1-[1-aryl-3-[4-(1H-imidazol-1-yl)phenyl]-3-oxo]propyl]-pyridine-2-carboxamidrazone derivatives

Antimycobacterial activity of new N(1)-[1-[1-aryl-3-[4-(1H-imidazol-1-yl)phenyl]-3-oxo]propyl]-pyridine-2-carboxamidrazone derivatives

  • Bioorg Med Chem Lett. 2016 Jul 15;26(14):3287-3290. doi: 10.1016/j.bmcl.2016.05.053.
Daniele Zampieri 1,  Maria Grazia Mamolo 2,  Luciano Vio 2,  Maurizio Romano 3,  Nataša Skoko 4,  Marco Baralle 4,  Valentina Pau 5,  Alessandro De Logu 5
Affiliations

Affiliations

  • 1 Department of Chemistry and Pharmaceutical Sciences, Piazzale Europa 1, University of Trieste, 34127 Trieste, Italy. Electronic address: dzampieri@units.it.
  • 2 Department of Chemistry and Pharmaceutical Sciences, Piazzale Europa 1, University of Trieste, 34127 Trieste, Italy.
  • 3 Department of Life Sciences, Via Valerio 28/1, University of Trieste, 34127 Trieste, Italy.
  • 4 ICGEB, International Centre for Genetic Engeneering and Biootechnology, Padriciano 99, 34149 Trieste, Italy.
  • 5 Department of Life and Enviromental Sciences, Via Porcell 4, University of Cagliari, 09124 Cagliari, Italy.
PMID: 27241693 DOI: 10.1016/j.bmcl.2016.05.053
Abstract

N(1)-[1-[1-aryl-3-[4-(1H-imidazol-1-yl)phenyl]-3-oxo]propyl]-pyridine-2-carboxamidrazone derivatives were design, synthesized and tested for their in vitro antimycobacterial activity. The new compounds showed a moderate antimycobacterial activity against the tested strain of Mycobacterium tuberculosis H37Ra and a significant antimycobacterial activity against several mycobacteria Other than tuberculosis strains.

Keywords

Antimycobacterial activity; Mycobacteria other than tuberculosis (MOTT); Pyridine-2-carboxamidrazone derivatives.

Figures